Advisory Committee to Review Boehringer Ingelheim's HIV Candidate Aptivus

The FDA's Antiviral Drugs Advisory Committee will convene May 19 to discuss Boehringer Ingelheim's new drug application for Aptivus.

The committee will consider Aptivus (tipranavir) as a treatment for patients with HIV. The drug is a nonpeptidic protease inhibitor (PI) that appears to work against HIV that is already resistant to other PIs. The drug has been tested in clinical trials using a twice-daily dosing combined with ritonavir.

If approved, Aptivus would be the second nonpeptidic PI approved in the U.S. Pfizer's Viracept (nelfinavir) was approved by the FDA in 1997.

For more information about the meeting, go to http://www.fda.gov/oc/advisory/accalendar/2005/cder12531d051905.html (http://www.fda.gov/oc/advisory/accalendar/2005/cder12531d051905.html).